MedTrace Logo

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

NCT03071679 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-05-22

No results posted yet for this study

Summary

This study has a randomized, evaluator-blinded, vehicle- controlled study to assess the pharmacodynamics of omiganan and omiganan with imiquimod in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

Omiganan

Omignan 1%, 2.5%

DRUG

Imiquimod

Imiquimod 15mg

DRUG

Omiganan 1% and Imiquimod

Omiganan 1% and Imiquimod

DRUG

Omiganan 2.5% and Imiquimod

Omiganan 2.5% and Imiquimod

DRUG

Placebo

Vehicle

Sponsors & Collaborators

  • Maruho Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • J. (Koos) Burggraaf, MD, PhD · Centre for Human Drug Research

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-06
Primary Completion
2017-03-07
Completion
2017-03-07

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03071679 on ClinicalTrials.gov